Clinical Trial Update: Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated the combination of alisertib and pembrolizumab in RB-deficient head and neck squamous cell carcinoma; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Alisertib (alisertib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-16